Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 4,234,144 shares, an increase of 76.1% from the July 15th total of 2,404,454 shares. Approximately 10.4% of the company’s stock are sold short. Based on an average trading volume of 52,873,116 shares, the days-to-cover ratio is currently 0.1 days.

Liminatus Pharma Price Performance

LIMN traded down $0.01 on Tuesday, hitting $0.13. The company had a trading volume of 1,165,831 shares, compared to its average volume of 20,847,688. The company’s fifty day moving average price is $0.12 and its 200 day moving average price is $0.25. Liminatus Pharma has a 1-year low of $0.10 and a 1-year high of $4.06. The stock has a market cap of $6.73 million, a price-to-earnings ratio of -0.28 and a beta of 5.34.

Liminatus Pharma (NASDAQ:LIMN) last announced its earnings results on Friday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.